Related Experiment Videos
HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma
W Blumenfeld1, J Q Ye, R Dahiya
1Department of Anatomic Pathology, Department of Veteran Affairs Medical Center, San Francisco.
The Journal of Urology
|October 1, 1993
Summary
Chronic prostatitis involves lymphocytic infiltration of benign prostate cells, which express HLA-DR. Interferon-gamma can induce HLA-DR on malignant prostate cancer cells, suggesting potential immune regulation strategies.
Area of Science:
- Immunology
- Urology
- Cell Biology
Background:
- Chronic prostatitis is poorly understood, marked by lymphocytic infiltration of benign prostatic epithelium.
- Prostate cancer cells typically do not express HLA-DR and are not infiltrated by lymphocytes.
- Benign prostatic epithelium expresses HLA-DR only when lymphocytic inflammation is present.
Purpose of the Study:
- To investigate HLA-DR expression in benign and malignant prostatic epithelium.
- To determine if HLA-DR is inducible on malignant prostate cancer cells for potential immune regulation.
Main Methods:
- Studied HLA-DR expression in benign prostatic epithelium with and without chronic prostatitis.
- Cultured DU-145 prostate cancer cells under various conditions, including exposure to cytokines.
- Assessed HLA-DR expression using flow cytometry or immunohistochemistry.
Main Results:
- Benign prostatic epithelium expresses HLA-DR exclusively in the presence of lymphocytic inflammation.
- Malignant prostatic epithelium (DU-145 cells) did not express HLA-DR under normal conditions.
- Interferon-gamma, but not other tested cytokines, induced HLA-DR expression on DU-145 cells within 72 hours.
Conclusions:
- Interferon-gamma can induce HLA-DR expression on the DU-145 prostate adenocarcinoma cell line.
- This induction raises the theoretical possibility of making malignant prostate cells susceptible to immune regulation in vivo.